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Abstract
Background: The presence of impaired glucose tolerance (IGT) and metabolic syndrome (MetS) are two risk factors
for Type 2 diabetes. The inter-relatedness of these factors among adolescents is unclear.
Methods: We evaluated the sensitivity and specificity of MetS for identifying IGT in an unselected group of
adolescents undergoing oral glucose tolerance tests (OGTT) in the National Health and Nutrition Evaluation Survey
1999–2010. We characterized IGT as a 2-hour glucose ≥140 mg/dL and MetS using ATP-III-based criteria and a
continuous sex- and race/ethnicity-specific MetS Z-score at cut-offs of +1.0 and +0.75 standard deviations (SD)
above the mean.
Results: Among 1513 adolescents, IGT was present in 4.8%, while ATP-III-MetS was present in 7.9%. MetS performed
poorly in identifying adolescents with IGT with a sensitivity/specificity of 23.7%/92.9% for ATP-III-MetS, 23.6%/90.8%
for the MetS Z-score at +1.0 SD and 35.8%/85.0 for the MetS Z-score at +0.75 SD. Sensitivity was higher (and specificity
lower) but was still overall poor among overweight/obese adolescents: 44.7%/83.0% for ATP-III-MetS, 43.1%/77.1% for
the MetS Z-score at +1.0 SD and 64.3%/64.3% for MetS Z-score at +0.75 SD.
Conclusion: This lack of overlap between MetS and IGT may indicate that assessment of MetS is not likely to be a
good indicator of which adolescents to screen using OGTT. These data further underscore the importance of other
potential contributors to IGT, including Type 1 diabetes and genetic causes of poor beta-cell function. Practitioners
should keep these potential causes of IGT in mind, even when evaluating obese adolescents with IGT.
Keywords: Insulin resistance, Metabolic syndrome, Impaired glucose tolerance, Type 2 diabetes, Adolescents

Introduction
The persistent high prevalence of pediatric obesity has
greatly increased risk of Type 2 diabetes mellitus
(T2DM) in the current generation of children and adolescents, increasing the need for effective tools to predict
those at highest risk [1,2]. One sensitive and specific
marker of impending T2DM is impaired glucose tolerance (IGT), defined as a blood glucose (BG) ≥140 mg/dL
at 2 hours after an oral glucola load as part of a fasting oral
glucose tolerance test (OGTT) [3,4]. In a study of children
and adolescents referred to an obesity treatment clinic,
24% of those with IGT at baseline progressed to have
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T2DM over a follow-up period of 20 +/− 10 months,
while none of the children with normal glucose tolerance
progressed to T2DM over the same time frame [5,6].
These findings are in contrast to a study of early adolescent European children that showed a high reversion to
normal glucose tolerance over a 1-year period [7]. Nevertheless, IGT may also be an early marker of risk, with increased rate of IGT noted even among adolescents with
rising fasting glucose levels in the normal range [8].
While OGTT’s are labor- and time-intensive tests, the
ADA recognizes them as one option in screening for
T2DM risk [9]. It should be noted, however, that IGT
does not distinguish between risk of T2DM and early,
pre-clinical signs of Type 1 diabetes mellitus (T1DM),
which results in elevated post-glucola BG due to insufficient insulin secretion [10].
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Another important potential tool to screen for risk of
T2DM is a set of criteria to identify the metabolic syndrome (MetS), a cluster of cardiovascular risk factors
that occur together more often than would be expected
by chance [11]. These factors include central obesity,
hypertension, hypertriglyceridemia, low HDL-cholesterol,
and elevated fasting glucose [12] and show in increase in
prevalence with age [13]. MetS appears to be associated
with insulin resistance in adolescents in that increasing
degrees of insulin resistance as determined by homeostasis
model [14,15] and hyperinsulinemic clamp [16] are significantly associated with risk of MetS and/or its individual
components. While the pathophysiology of T2DM consists of multiple overlying factors, including insulin resistance, excess hepatic glucose release and defects in
adequate insulin production [17,18], the potential utility
for MetS to identify risk in adolescents for future T2DM
was demonstrated in that adolescents with MetS (compared to those without MetS) have an odds ratio (OR) of
10 for developing T2DM by age 32 [19].
It is unknown what the short-term risk of progression
to T2DM is among adolescents with MetS; however,
MetS appears to be a less specific marker than IGT of
imminent risk of T2DM, given that MetS is classified in
8.6% percent of adolescents in the US [20] while the
prevalence of T2DM among US adolescents in the
SEARCH study was estimated at only 0.042% [21]. In
addition, MetS exhibits racial/ethnic discrepancies that
may limit its widespread use as a screening tool [22,23].
In particular, when using traditional MetS criteria based
on the Adult Treatment Panel III (ATP-III), nonHispanic black individuals are less likely to be classified
as having MetS despite having more insulin resistance
and more T2DM [24-26]. Because of these racial/ethnic
differences, we have recently formulated a sex- and race/
ethnicity-specific MetS severity score for use among adolescents [27]. This continuous estimate of MetS severity
is a Z-score (range from negative infinity to positive infinity, with a mean of 0) is calculated based on an adolescent’s values for each of the components of MetS,
with weighting of these components that is determined
by confirmatory factor analysis of how these components cluster by sex- and racial/ethnicity and is unique
to each subgroup [28]. This score appears less likely to
exhibit racial ethnic differences in the association of
MetS with surrogate markers of T2DM risk, such as
elevated fasting insulin [27].
Our goal was to evaluate the potential for MetS to
identify individuals with IGT, as an important precursor
to T2DM. We utilized data from the National Health
and Nutrition Evaluation Survey (NHANES) data with
two hypotheses: 1) that traditional MetS would have a
high sensitivity and specificity for predicting IGT and 2)
that our sex- and race/ethnicity-specific risk score would
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exhibit improved sensitivity to identify adolescents with
IGT. In doing so we hoped to clarify relationships between these markers of long-term risk T2DM risk
among adolescents.

Methods
Data were obtained from NHANES (1999–2010), a complex, multistage probability sample of the US population.
These annual cross-sectional surveys are conducted by
the National Center for Health Statistics (NCHS) of the
Centers for Disease Control (CDC), with randomlyselected participants undergoing anthropometric and
blood pressure measurements, answering questionnaires
and undergoing phlebotomy (http://www.cdc.gov/nchs/
nhanes.htm). The NCHS ethics review board reviewed
and approved the survey and participants gave informed
consent prior to participation.
Height, weight, BMI, WC, blood pressure (BP), and laboratory measures of triglycerides, HDL-C, and glucose
were obtained using standardized protocols and calibrated equipment [29]. All blood samples used for analyses were obtained following a ≥8 hours fast.
A fasting oral glucose tolerance test was performed on
a random sub-set of adolescent participants of NHANES.
After their fasting glucose assessment, participants were
given 1.75 g/kg of glucola to a maximum of 75 g. Two
hours after this ingestion a second blood draw was obtained to assess 2-hour glucose level.
Data from non-Hispanic-white, non-Hispanic-black, or
Hispanic (Mexican-American/other Hispanic) adolescents 12-19 y were analyzed. Children <12 y were excluded since fasting values for triglycerides and glucose
were only obtained in participants ≥12 y. Participants
with known diabetes (T1DM or T2DM) were excluded
by eliminating those with self-reported diabetes and
those on anti-diabetic medications. Participants were
also excluded if they were pregnant or taking antihyperlipidemic medications as these are likely to alter lipid
and glucose levels in a manner that may reflect baseline
relationships between MetS and glucose tolerance. Individuals taking anti-hypertensive medication were classified as having hypertension.
IGT and MetS classification

IGT was classified for a two-hour blood glucose of
≥140 mg/dL. MetS status was evaluated in two manners:
1) A commonly-used pediatric/adolescent adaptation of
the Adult Treatment Panel III (ATP III) criteria [20,29].
Participants had to meet ≥3 of the following 5 criteria:
concentration of triglycerides ≥110 mg/dL, HDL-C
≤40 mg/dL, WC ≥90th percentile for age/sex (or ATP III
limit of 102 cm for males and 88 cm for females, whichever was lower) [12,30], glucose concentration ≥100 mg/dL,
and systolic or diastolic BP ≥90th percentile (age,
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height, and sex-specific) [31]. Similarly, hypertension
was defined as systolic or diastolic BP ≥90th percentile
for age, height, and sex. 2). Using a pediatric-adolescent
continuous metabolic syndrome severity Z-score [27].
This score is based on a factor analysis of the contributions of individual MetS components on a sex- and
race/ethnicity-specific basis. The sex- and race/ethnicity-specific equations have been published previously
[27] and are available as an online calculator (http://
publichealth.hsc.wvu.edu/biostatistics/mets).
Statistical analysis

Statistical significance was defined as a p-value < 0.05.
Statistical analysis was performed using SAS (version
9.3, Cary, NC). Prevalence rates of MetS were calculated
by glucose tolerance category, and compared via chisquare tests. The presence of insulin resistance was categorized based on an elevated fasting insulin ≥16.0 IU/
mL, approximately the 95th percentile among lean adolescents in NHANES [25] and used elsewhere previously
[32-34]. Receiver operating characteristic (ROC) analysis
was used to assess the ability of the sex- and race/ethnicity-specific MetS Z-score to discriminate IGT. Overall
predictive performance was measured by the area under
the curve (AUC) of the ROC curve, with AUC of 0.5
and 1.0 indicating no and perfect predictive ability, respectively. Sensitivities and specificities to predict the
presence of IGT were compared between the traditional
MetS classification and using cut-offs of the MetS severity Z-score. This includes Z-score cut-offs as follows: 1)
1.0 to approximate the prevalence of ATP-III MetS and
2) 0.75 assess the performance of a more liberal definition of MetS. These statistics were done on a sex and
race/ethnicity-specific basis. All analyses, except for the
ROC analysis, accounted for the survey design of
NHANES in producing population-based estimates of
basic descriptive statistics as well as prevalences, sensitivities, and specificities.

Results

Page 3 of 8

0.01) and high fasting glucose (15.2% vs. 37.6%, p <
0.001). Adolescents with IGT had higher levels of fasting
insulin (18.9 IU/mL vs. 11.8 IU/mL) and a higher prevalence of fasting insulin above 16.0 (the 95th percentile
among lead adolescents, 51.9 vs. 20.1, p < 0.0001). HbA1c
values were similar between groups, as was the MetS
Z-score.
Ability of MetS classification to identify IGT

Overall a classification of MetS exhibited poor sensitivity
but reasonable specificity for the identification of IGT.
Using traditional MetS criteria in the overall population,
a classification of MetS had a sensitivity of 23.7% and
specificity of 92.9% for detecting IGT, while using a
MetS Z-score cut off of 1.0 (to yield similar MetS prevalence as found by traditional MetS criteria) had a sensitivity of 23.6% and specificity of 90.8% (Figure 1). The
overall poor sensitivity was also noted among adolescents who were overweight/obese, for whom ATP-III
MetS had a sensitivity of 44.7% and specificity of 83.0%
for detecting IGT, while using a MetS Z-score cut off of
1.0 had a sensitivity of 43.1% and specificity of 77.1%. As
expected, using a more liberal MetS Z-score cut-off of
0.75 yielded higher sensitivity values (35.8% overall and
64.3% among those overweight/obese) and lower specificity values (85.0% overall and 64.3% among those overweight). When evaluated by race/ethnicity, both MetS
measures yielded lower sensitivity among non-Hispanic
whites compared to non-Hispanic blacks and Hispanics
(Table 2). Compared to ATP-III MetS, the MetS Z-score
at a cut-off of 1.0 had lower sensitivity among nonHispanic whites (11.2% vs. 17.4%) but higher sensitivity
among non-Hispanic blacks (55.9% vs. 31.8%) and similar among Hispanics (37.1% vs. 34.1%).
ROC curve analysis of the race/ethnicity-specific Adolescent MetS Z-score to identify participants with IGT
revealed an area-under-the-curve of 0.67 among the
overall group (Figure 2). When evaluated among only
those adolescents who were overweight/obese this areaunder-the-curve was 0.64.

Participant characteristics

We analyzed a study sample consisting of 1513 nonHispanic-white, non-Hispanic-black and Hispanic adolescents age 12-19 y with data for all variables tested.
Overall 4.8% of participants exhibited IGT while 7.92%
were classified as having MetS (Table 1). Compared to
those with normal glucose tolerance, those with IGT
were older, had a higher BMI and a higher rate of ATPIII MetS classification. With the exception of fasting glucose, there were no significant differences in raw values
of individual MetS components, though compared to adolescents with normal glucose tolerance, adolescents
with IGT had a higher prevalence of elevated WC
(21.3% vs. 44.7%, p < 0.01), high BP (7.4% vs. 21.4%, p <

Discussion
In this sample of adolescents who received an OGTT as
part of NHANES, we were surprised to find a relatively
poor association between two important markers of risk
for T2DM: MetS and IGT. While these processes are
clearly linked—seen in a 3-fold higher prevalence of
MetS among adolescents with IGT—we found that the
majority of cases of IGT were not associated with MetS,
either using traditional ATP-III criteria or using a sexand race/ethnicity-specific linear MetS Z-score. This low
prevalence of MetS in IGT was true both in the overall
population and in a sub-set of adolescents who were
overweight/obese and thus more likely to experience the
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Table 1 Participant characteristics
Overall

Normal glucose tolerance

Impaired glucose tolerance

1513

1441

72

Mean (95% CI) Age

15.55 (15.38, 15.71)

15.60 (15.43, 15.76)

14.47 (13.75, 15.20)

0.0030

Percent (95% CI) Male

49.94 (45.06, 54.82)

50.33 (45.22, 55.44)

41.98 (22.68, 61.28)

0.4146

Mean (95% CI) BMI

N

p-value*

23.87 (23.39, 24.34)

23.80 (23.34, 24.25)

25.35 (22.47, 28.24)

0.2797

Mean (95% CI) BMI Z-score

0.66 (0.57, 0.74)

0.65 (0.57, 0.73)

0.93 (0.37, 1.49)

0.3062

Percent (95% CI) with ATP-III MetS

7.92 (5.77, 10.06)

7.14 (5.00, 9.29)

23.74 (8.75, 38.73)

0.0009

MetS Components
Waist Circumference
Mean (95% CI)

82.21 (80.91, 83.50)

82.00 (80.72, 83.28)

86.45 (78.86, 94.05)

0.2486

th

22.42 (19.01, 25.83)

21.34 (17.82, 24.85)

44.66 (27.32, 61.99)

0.0022

Mean (95% CI)

85.91 (81.65, 90.17)

84.42 (80.53, 88.32)

116.34 (78.83, 153.84)

0.0952

Percent (95% CI) ≥ 110

21.60 (18.53, 24.68)

21.01 (18.19, 23.82)

33.82 (15.83, 51.81)

0.0806

Mean (95% CI)

53.00 (52.03, 53.97)

53.07 (52.08, 54.06)

51.54 (47.06, 56.03)

0.5079

Percent (95% CI) ≤ 40

11.46 (9.13, 13.78)

11.11 (8.82, 13.40)

18.63 (5.64, 31.61)

0.1541

109.91 (108.87, 110.95)

109.83 (108.80, 110.87)

111.46 (105.90, 117.03)

0.5608

8.01 (5.82, 10.20)

7.36 (9.57, 5.14)

21.42 (8.08, 34.76)

0.0025

Mean (95% CI)

93.09 (92.36, 93.82)

92.90 (92.19, 93.62)

96.96 (93.86, 100.06)

0.0104

Percent (95% CI) ≥ 100

16.27 (13.41, 19.13)

15.23 (12.48, 17.99)

37.60 (21.08, 54.11)

0.0003

5.26 (5.24, 5.28)

5.26 (5.23, 5.28)

5.32 (5.23, 5.40)

0.1938

Percent (95% CI) ≥ 90 percentile
Triglycerides

HDL

Blood Pressure
Mean Systolic (95% CI)
Percent (95% CI) ≥ 90th percentile
Fasting Blood Glucose

Mean (95% CI) HbA1c
Mean (95% CI) fasting insulin

12.17 (11.49, 12.85)

11.84 (11.29, 12.49)

18.90 (14.28, 23.51)

0.0033

Percent (95% CI) insulin > 16 IU/mL

21.62 (18.61, 24.64)

20.14 (17.26, 23.03)

51.89 (36.40, 67.37)

< 0.0001

Mean (95% CI) MetS Z-score

−0.02 (−0.09, 0.05)

−0.04 (−0.10, 0.03)

0.32 (−0.20, 0.83)

0.1703

*t-test comparing means of continuous variables; chi-square test comparing percentages of binary variables (both accounting for survey design).

processes underlying MetS, such as adipocyte dysfunction and oxidative stress. Altogether, this lower-thananticipated association between MetS and IGT may
implicate a predominance of non-MetS causes of IGT in
adolescents.
The low association of MetS with IGT in adolescents
is likely related to the complex physiology of glucose
control. Elevations in BG following a glucose challenge
are influenced by insulin release and tissue responsiveness to insulin [17]. Insulin release following glucose ingestion occurs in two phases: an initial spike (the first
phase, blunting of which is an early occurrence in the
pathophysiology of T2DM) and a second more gradual
rise that can be heightened in T2DM but remains inadequate to lower BG [35]. Insulin secretion is influenced
by underlying genes affecting beta cell function (which
constitute the largest group of genes implicated in
T2DM pathogenesis in large-scale evaluations [18]) but
can be suppressed further by elevations in lipids [36,37]
and glucose itself [38], as well as dysfunction of other

hormones including the incretin GLP-1 [17]. Insulin resistance can contribute to BG elevations by necessitating
that beta cells secrete higher amounts of insulin to mediate sufficient glucose disposal. Once the minimum
threshold of insulin level for maintenance of BG levels is
exceeded, post-prandial BG begins to rise. The combination of inadequate insulin secretion and insulin resistance is the primary cause of IGT and subsequent
diabetes in adults [39-41].
Among children and adolescents, the major cause of
IGT is unknown, while the major cause of diabetes remains isolated defects in insulin production as seen following auto-immune beta cell destruction in T1DM,
with a prevalence of 0.23% among adolescents compared
to a prevalence of 0.042% for T2DM in this age range
[21]. Limitations in insulin release are also seen in
monogenic forms of diabetes such as the group of genes
comprising MODY, also with a low overall prevalence at
approximately 1% of pediatric diabetes cases [42,43].
Whereas insulin resistance and MetS are more prevalent
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Figure 1 Metabolic syndrome in adolescents: prevalence and sensitivity and specificity to identify impaired glucose tolerance (IGT).
A and C: Prevalence and 95% confidence intervals of MetS among all adolescents (A) and among only those overweight or obese (C), using
ATP-III MetS criteria and MetS Z-score with cut-offs of 1.0 and 0.75. B and D: Sensitivity (dark grey bars) and specificity (light grey bars) and 95%
CI of MetS for identifying IGT among all adolescents (B) and among only those overweight or obese (D).

in overweight/obese children and adolescents [44] (contributing to an improved sensitivity of MetS for IGT identification among overweight/obese adolescents, Table 2),
primary defects in insulin release such as T1DM and
MODY would be expected to be present across the weight
spectrum in childhood. T1DM itself, if poorly controlled,
is clearly associated with abnormalities in MetS components, particularly hypertriglyceridemia and low HDL
[45], further complicating the potential relationships between MetS and IGT. We excluded participants with
known diabetes from our analysis, but it is possible that a
small percentage of the adolescents in our sample had
early, undiagnosed T1DM or MODY [10]. Nevertheless,
the proportion of all participants in our sample with nonMetS IGT (3.6%) far exceeded the expected number of
cases of undiagnosed T1DM and MODY (which together
have an incidence of 0.022% per year in childhood
[21,46]), potentially suggesting a high prevalence of other
limitations of insulin secretion, including polygenic defects in beta-cell function that have been implicated in
T2DM in adults [18,47].
We hypothesized that one limitation in the ability of
MetS to identify individuals with IGT was due to variation in the diagnostic accuracy of MetS criteria by racial/ethnic group [22-26]. Because of this, we performed

our analysis using both a common adolescent adaptation
of ATP-III MetS criteria [20,29], as well as a sex- and
race/ethnicity-specific MetS severity score [27]. This severity score has the potential to have cut-off levels
adjusted based on outcomes-based data (which we currently lack) or based on a desire to identify higher numbers of adolescents at risk. In using this score we first
tested a cut-off level of 1 standard deviation above the
mean, which provides prevalence of MetS similar to that
determined by ATP-III criteria—and which produced
sensitivity values for IGT prediction similar to ATP-III
criteria. We then tested a more liberal cut-off of 0.75
standard deviations above the mean, exhibiting increased
sensitivity but worsened specificity compared to ATPIII-based criteria. This type of approach could be used
to improve identification of adolescents at increased risk
for long-term diseases associated with MetS—which
could be important since improved tools for risk detection are badly needed to target interventions to help
avert disease progression [23].
The MetS Z-score exhibited a differential response in
IGT prediction by racial/ethnic group, with the score
overall exhibiting worsened sensitivity among nonHispanic white adolescents (using a MetS Z-score cutoff 1.0, sensitivity was 11.2% vs. 17.4% for ATP-III MetS)
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Table 2 Sensitivity and specificity (and 95% confidence intervals) of metabolic syndrome to predict impaired glucose
tolerance by racial/ethnic group among adolescents overall and among those who are overweight/obese
Adolescents BMI ≥ 85th percentile

All adolescents
NHW

ATP-III MetS

MetS Z > 1.0

MetS Z > 0.75

NHB

ATP-III MetS

MetS Z > 1.0

MetS Z > 0.75

Hispanic

ATP-III MetS

MetS Z > 1.0

MetS Z > 0.75

Prevalence of “Mets”

Sensitivity

Specificity

Prevalence of “Mets”

Sensitivity

Specificity

7.43

17.36

93.01

18.57

43.97

82.74

(4.46, 10.41)

(0.00, 35.00)

(90.03, 96.00)

(10.33, 26.80)

(9.21, 78.72)

(74.68, 90.79)

8.33

11.17

91.79

22.09

28.29

78.22

(5.27, 11.40)

(0.00, 24.47)

(88.79, 94.79)

(14.28, 29.91)

(0, 58.82)

(70.65, 85.80)

14.48

23.63

85.92

36.64

59.85

64.55

(10.18, 18.79)

(2.81, 44.44)

(81.60, 90.26)

(27.13, 46.15)

(27.78, 91.93)

(54.95, 74.14)

4.40

31.82

96.55

9.91

34.33

91.99

(2.10, 6.69)

(1.06, 62.58)

(94.64, 98.46)

(4.90, 14.92)

(1.92, 66.75)

(87.67, 96.32)

7.73

55.91

93.94

17.39

60.33

85.95

(5.00, 10.46)

(24.42, 87.40)

(91.58, 96.31)

(11.89, 22.89)

(28.88, 91.78)

(9.33, 18.77)

13.18

69.32

88.76

29.90

74.80

74.59

(8.14, 18.22)

(41.80, 96.83)

(84.18, 93.35)

(19.23, 38.71)

(48.27, 100)

(65.08, 84.10)

12.49

34.06

89.12

26.13

51.33

76.68

(8.65, 16.32)

(12.39, 55.73)

(85.82, 92.42)

(18.94, 33.32)

(27.67, 74.99)

(16.60, 30.04)

16.90

37.07

84.61

35.15

52.19

66.75

(12.63, 21.16)

(15.71, 58.42)

(80.82, 88.39)

(27.67, 42.62)

(28.83, 75.53)

(59.65, 73.85)

23.49

48.17

78.35

46.73

64.02

55.20

(18.60, 28.38)

(26.73, 69.60)

(73.82, 82.89)

(38.97, 54.49)

(42.70, 85.35)

(47.59, 62.80)

but an improved sensitivity among non-Hispanic blacks
(55.9% vs. 31.8%). This improvement in sensitivity
among non-Hispanic black adolescents may not be surprising, since traditional MetS criteria utilize populationbased cut-off values for the individual components and
do not take into account that non-Hispanic-black adolescents have lower baseline levels of triglycerides and
are less likely to exhibit abnormalities in triglycerides or
HDL despite having more insulin resistance and higher
rates of diabetes [24-26]. These inter-ethnicity differences are what stimulated our formulation of the sexand race/ethnicity-specific MetS Z-score in the first
place. Overall, the MetS Z-score appeared to work best
in the identification of non-Hispanic black adolescents
with IGT, though we were limited in many of our comparisons between racial/ethnic groups by the small sample size of adolescents in NHANES who underwent
OGTT’s and by the overall lower prevalence of IGT.
However, while we noted an increased sensitivity using
a lower cur-off of the race/ethnicity-specific MetS Zscore, the presence of MetS overall was a poor screening
test to identify adolescents with IGT. Acceptable degrees
of sensitivity and specificity in a screening test depend
on the importance of the outcome being screened for
and the downside to missing detection of that outcome.
In this case, the specificity of these tests was overall reasonable clinically, 78-97% among all adolescents. However, the low sensitivity and thus number of non-MetS

cases of IGT reflects the potential for false reassurance
regarding the risk of IGT in an adolescent based on the
absence of MetS.
Interestingly, there appeared to be a sizable number of
cases of elevated fasting insulin levels (as an estimate of

Figure 2 ROC curve of metabolic syndrome Z-score for identifying
impaired glucose tolerance (IGT). ROC curve among all adolescents
using MetS Z-score. AUC = area under curve.
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insulin resistance) in this sample that were not identified
by ATP-III MetS or our MetS Z-score. Among adolescents with IGT there was a higher prevalence of elevated
fasting insulin—present in 52% of adolescents with IGT—
than of ATP-III MetS (24%) or any of the individual components of MetS (with prevalences of 19-45%). There is a
clear difficulty in using measures of fasting insulin as an
estimate of insulin resistance in settings of glucose excursions, since the mere elevation of BG implies a limitation
in secretion of adequate amounts of insulin to normalize
BG. Additionally, while fasting insulin correlates highly
with other surrogate markers of insulin resistance
(HOMA-IR, QUICKI), it clearly lacks the precision of
more robust measures of insulin resistance, such as an insulin clamp [44,48]. Thus, our measure of those with elevated insulin levels (fasting insulin above 16.0 IU/mL,
approximately the 95th percentile among lean adolescents
in NHANES [25] and used elsewhere [32-34]) may not reflect the full number of participants with insulin resistance. Overall, however, there were 48% of children with
IGT who did not exhibit elevations in fasting insulin,
again suggesting a high prevalence of IGT unrelated to insulin resistance.
This study had multiple limitations, including the crosssectional design of NHANES, which limits any conclusions regarding causality. In addition, while NHANES
often represents a powerful study, there was only a small
subset of adolescents who underwent the OGTT. Finally,
we lacked important additional information such as antibodies associated with T1DM as well as genetic information on participants.
In conclusion, we found that the presence of MetS
and elevated fasting insulin in adolescents had a poor
correlation with IGT, an important precursor T2DM as
well as a potential finding during the short presymptomatic phase of T1DM. This lack of overlap between MetS and IGT may indicate that assessment of
MetS is not likely to be a good indicator of which adolescents to screen using an OGTT. These data further
underscore the need for further research to assess for
other potential contributors to IGT, including T1DM,
MODY and polymorphisms associated with poorer betacell function. Practitioners should keep in mind other
potential causes of IGT, even when evaluating obese adolescents with IGT.
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